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Background: Osimertinib improve therapy for non-small cell lung cancer (NSCLC). However, invariable 
acquired resistance appears. 
Methods: MTT assay was used to analyze cell viability. Protein expression and activation was detected by 
Western blotting. In addition, the effects of heat shock protein 90 (Hsp90) inhibitors and osimertinib were 
studied in colony formation assays.
Results: Our laboratory generated osimertinib resistant cell lines from PC9 cell line and overexpression 
or activation of several proteins was detected. Hsp90 inhibitors, ganetespib and luminespib, inhibited 
cell viability and colony formation in H1975, PC9 and PC9-derived osimertinib-resistant cell lines and 
combination of these inhibitors with osimertinib achieved to enhance this cell viability and colony formation 
inhibition. Luminespib downregulated the expression of the several proteins involved in osimertinib-
resistance and the combination of this compound plus osimertinib caused an important decrease of 
expression of several of these proteins, such as Stat3, Yap, Akt, EGFR and Met. Osimertinib activated the 
phosphorylation of several membrane receptors and downstream molecules that was partially inhibited by 
luminespib. In addition, a lung cancer patient with an EGFR eon 20 mutation had a partial radiographic 
response to ganetespib. 
Conclusions: Hsp90 inhibitors and osimertinib exhibits a good efficiency to inhibit cell viability, colony 
formation and inhibits expression and activation of proteins involved in osimertinib-resistance and may 
represent an effective strategy for NSCLC with intrinsic resistance to osimertinib inhibition.
Keywords: Heat shock protein 90 (Hsp90); osimertinib; non-small cell lung cancer (NSCLC); epidermal growth 
factor receptor (EGFR); resistance
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Introduction
Epidermal growth factor receptor tyrosine kinase inhibitors 
(EGFR-TKIs) are one of the most important treatments 
in non-small cell lung cancer (NSCLC) EGFR mutated 
patients. Osimertinib (also named AZD9291 or Tagrisso) is 
one EGFR-TKI that has been approved by the Food Drug 
Administration (FDA) for treating patients with EGFR 
T790 mutant NSCLC with disease progression on or after 
EGFR TKI progression. Although first-generation EGFR 
TKIs provide significant clinical benefit, acquired resistance 
often occurs, most commonly via a T790M resistance 
mutation. Osimertinib is selective for both T790M and 
activating EGFR mutations over wild-type EGFR, but 
it is highly active when T790M is present, especially 
EGFR(L858R/T790M), and modestly active when T790M 
is absent (1,2). Despite good initial response, resistance to 
osimertinib appears (3-6). The mechanisms of resistance 
could be divided into two groups: EGFR dependent and 
EGFR independent. In the first group, C797S mutation in 
EGFR exon 20 is the main cause of resistance. In addition, 
T790 mutation reduction or disappearance, EGFR 
amplification and high EGF levels are involved in resistance 
to osimertinib. EGFR-independent mechanisms that 
cause osimertinib-resistance have been described, such as, 
HER2 (7) or Met amplification, PIK3CA, KRas, NRas or 
BRAF mutations, PTEN loss, activation of RAS-MAPK or 
IGF-1R pathways, as well as the FGF-FGFR1 autocrine 
loop and epithelial-mesenchymal transition (EMT) (8).
An important therapeutic strategy for osimertinib-
resistant NSCLC due to EGFR-dependent resistance 
mechanisms, is the use of anti-EGFR monoclonal 
antibodies, such as, cetuximab or panitumumab, alone, 
or in combination with other drugs, like, EA1045 or 
Brigatinib (6). When EGFR-independent resistance 
mechanisms are evident, the therapeutic strategies are to 
combine osimertinib plus crizotinib or inhibitors of MET, 
MEK, BRAF, PI3K, SFK, FAK or AXL (6). In addition, 
osimertinib resistant patients with SCLC transformation 
were treated with platinum-based doublet chemotherapy (9). 
It has also been described that the PD-L1 expression was 
increased in osimertinib-resistant NSCLC (10) and it has 
been postulated that PS-L1/PD-1 antibodies might be a 
new promising treatment for osimertinib-resistant patients 
with high PD-L1 expression (6).
Heat shock protein 90 (Hsp90) is highly expressed in 
most tumors (11). Because tumors cells are often protein 
misfolded, it implies the need for correct folding and more 
Hsp90 activity (12) and, for this reason, tumors tend to 
be more sensitive to Hsp90 inhibition (13). Hsp90 plays 
a crucial role in maintaining cellular protein homeostasis 
because it regulates protein maturation, folding and 
stability, and plays a critical role in differentiation, cell 
growth and survival (14). Thus, Hsp90 could be an 
attractive therapeutic target and several clinical trials are 
being opened or are in progress with Hsp90 inhibitors 
alone or in combination with other drugs (15).
Hsp90 inhibitors induce the proteosomal degradation 
of Hsp90 client proteins such as EGFR, HER2, IGF-
1R, Stat3, Akt, Raf-1, IKK, c-Kit, v-Src, NPM-Alk, p53, 
HIF-1 and CD4/6 (16,17). In addition, Akt-activated 
tumors are sensitive to Hsp90 inhibitors (18) and indirectly 
downregulate Mcl1 expression by inhibiting Akt and Erk1/2 
signaling (19).
Hsp90 inhibitors, such as Ganetespib and Luminespib, 
have been assayed in clinical trials in several tumor types, 
such as NSCLC (20,21), colon (22), breast (23), prostate 
(24,25), myeloma (26,27) and melanoma (28). It has been 
demonstrated that they overcome resistance to EGFR-
kinase inhibitors (18).
Unfortunately, these inhibitors showed limited efficacy 
as a single agent, however, they are still in various stages 
of clinical trials as a component for combination therapies 
(16,29). Luminespib used as a single agent in a phase II 
study in lung cancer patients showed poor effectiveness 
(16,29).
Recently, the results have been published of a phase II 
study with Luminespib in pretreated patients with stage 
IV NSCLC. This compound is active in these patients, 
particularly among patients with ALK rearrangements and 
EGFR mutations (30). In addition, EGFR exon 20 insertion 
mutations display sensitivity to Hsp90 inhibition in lung 
adenocarcinomas and cellular models (31,32).
In our study we investigate whether the Hsp90 inhibitors, 
luminespib and ganetespib, could overcome osimertinib-
resistance in EGFR-mutated NSCLC cell lines.
Methods
Cell lines 
Human lung adenocarcinoma PC-9 cells, harboring 
EGFR exon 19 deletion (E746-A750) were provided by 
F. Hoffmann-La Roche Ltd. with the authorization of 
Dr. Mayumi Ono (Kyushu University, Fukuoka, Japan). 
Human lung adenocarcinoma H1975 cells, harboring both 
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sensitizing L858R and resistant T790M mutation, were 
purchased from the American Type Culture Collection 
(ATCC). PC9-OR2 and PC9-OR4 are osimertinib-resistant 
cells, the two lines were generated in our laboratory 
by exposing PC9 cells to increasing concentrations of 
the osimertinib (33). All cell lines were maintained in 
Roswell Park Memorial Institute (RPMI) 1640 Medium 
supplemented with 1% penicillin/streptomycin/glutamine 
(Gibco) and 10% fetal bovine serum (FBS) (Gibco) in 
5% CO2, 37 ℃ cell culture incubator and were routinely 
evaluated for mycoplasma contamination. Media and 
supplements were obtained from Life Technologies 
(Gaithersburg, MD, USA).
Chemical and reagents
Osimertinib (AZD9291), luminespib (AUY922) and 
ganetespib (STA9090) were purchased from Selleck 
Chemicals (Houston, TX, USA). Drugs were prepared 
in dimethyl sulfoxide (DMSO) at a concentration of 
10–100 mmol/L stock solutions and stored at −20 ℃. 
Further dilutions were made in culture medium to final 
concentration before use. The following antibodies used 
were from Cell Signaling Technology (Beverly, MA, USA): 
EGFR (Cat#4267); phospho-EGFR (Tyr 1068) (Cat#3777); 
STAT3 (Cat#9139); phospho-STAT3 (Tyr705) (Cat#9145); 
AKT (Cat#9272); phospho-AKT (Ser473) (Cat#9271); 
ERK1/2 (Cat#9102); phospho-ERK 1/2 (Thr202/Tyr204) 
(Cat#9101); Bmi1 (Cat#6964); HES1 (Cat#11988); IGF-1R 
(Cat#9750); phospho-IGF-1R (Tyr 136) (Cat#6113) EphA2 
(Cat#6997); phospho-EphA2 (Ser 897) (Cat#6347); Met 
(Cat#8198); Axl (Cat#8661); Src (Cat#2109); phospho-Src 
(Tyr 416) (Cat#6943); Yap (Cat#12395); mTOR (Cat#2983); 
Bcl2 (Cat#15071); Bim (Cat#2819). phospho-Yap (Tyr 
357) (Cat#ab62751), h3 (Cat#ab1791) were purchased 
from Abcam (Cambridge, UK). phospho-h3 (Ser 10) 
(Cat#06-570) was purchased from Millipore and α-Tubulin 
from Sigma-Aldrich (Cat#T9026). Secondary antibodies 
horseradish linked peroxidase anti-rabbit (Cat#NA934), and 
horseradish linked peroxidase anti-mouse (Cat#NX931) 
antibodies were purchased from GE Healthcare.
Cell viability assay
The effects of different compounds on the cell viability of 
PC9, H1975, PC9-OR2 and PC9-OR4 were studied by use 
of the colorimetric (MTT). Two thousand (PC9, H1975) 
or 4000 (PC9-GR4, PC9-OR4) cells were seeded in 
100 µL 0.1% FBS media and incubated for 24 hours before 
treatment; 100 µL of various 2× drug concentration (1× final 
concentration) were added to the wells, and the cells were 
incubated for 72 hours. 
Cell viability was assessed by the Thiazolyl Blue 
Tetrazolium Bromide (MTT) (Sigma, St Louis, MO, USA) 
assay. Cells from each cell line were seeded at 2,000 to 
4,000 cells per well in 96-well plates, allowed to attach for 
24 h and treated for 72 h (for details of the combination 
experiments, see below). After treatment, cells were 
incubated with medium containing MTT (0.75 mg/mL in 
medium) for 1–2 h at 37 ℃. Culture medium with MTT 
was removed and formazan crystals reabsorbed in 100 µL 
DMSO (Sigma). Cell numbers were estimated by measuring 
the absorbance at 495 nm, using a microplate reader 
(BioWhittaker, Walkersville, MD, USA). The data reported 
represent the mean ± SD of a minimum of 3 experiments of 
each drug concentration tested. 
Western blotting 
For Western blot assays, cells were cultured in cell culture 
flasks and left untreated or treated as indicated in each 
experiment. Cells were lysed in ice-cold RIPA buffer [20 
mM Tris-HCl (pH:7.5), 150 mM NaCl, 1 mM EDTA, 1 
mM EGTA, 1% NP40, 1% sodium deoxycholate, 2.5 mM 
sodium pyrophosphate, 1 mM beta-glycerophosphate, 
1 mM Na3VO4, 1 µg/mL leupeptin, 1 mM PMSF]. 
After incubating for 20 min at 4 ℃, the samples were 
centrifuged, and the supernatant was kept at −80 ℃. 
Protein concentration was determined by bicinchoninic 
acid protein assay. Equal amounts of protein from each cell 
lysate (30 µg/lane) were subjected to SDS polyacrylamide 
gel electrophoresis (SDS/PAGE) and transferred onto 
polyvinylidene difluoride membranes (Millipore, New 
Bedford, MA, USA). The membranes were blocked in Tris-
buffered saline containing 5% fat free dry milk and then 
probed with primary antibodies at 4 ℃ overnight. After 
washing, the membrane was incubated with horseradish 
peroxidase-conjugated secondary antibodies for 2 hours at 
room temperature. Specific proteins were visualized with 
enhanced chemiluminescence detection reagent according 
to the manufacturer’s instructions (Pierce Biotechnology, 
Rockford, IL, USA) and analyzed by Chemidoc MP 
Imaging System (Bio Rad). β-actin was used as an internal 
control to confirm equal gel loading.
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Colony formation assay
PC9, H1975, PC9-OR2 and PC9-OR4 cells were seeded at 
200 cells per well in a 6-well plate and incubated overnight. 
The cells were treated with compounds, Osimertinib, 
Ganetespib or Luminespib, or DMSO as vehicle control. 
The culture media and compounds were changed every 
three days. On day 12 cell culture medium was removed and 
each well was washed with phosphate buffered saline (PBS). 
Then the colonies were stained with 0.5% of violet crystal 
at room temperature for 15 min and distilled water was used 
to wash the plates several times until the dye stops coming 
off and allowed to dry overnight. Images were captured and 
the number of colonies in each well was counted using J 
software.
Patient and case report
The clinical and radiographic data for this study was obtained 
from the medical reports of a patient treated in our institution. 
Patient signed and IRB-validated informed consent authorizing 
the anonymized use of her medical images for publication 
purposes following institutional and regional regulations 
and the review of data was conducted in accordance with 
recognized ethical guidelines. The Institutional Review Board 
was the Ethical Committee of Drug Research of Quirónsalud 
Hospitality Group (Barcelona, Spain).
Results
Protein characterization of osimertinib-resistant cell lines 
We established five osimertinib-resistant cell lines from the 
parental NSCLC cell line, PC9. This cell line was treated 
with increased concentrations of osimertinib, as described, 
thus generating the osimertinib-resistant cell lines. PC9 
cells were treated with an increased concentration of 
osimertinib for 10 cycles and the 10th generation resistant 
cells were named PC9-OR1, PC9-OR2, PC9-OR3, PC9-
OR4 and PC9-OR5 (PC9-ORs). The IC50 values for 
osimertinib of these cell lines are described in Figure 1.
We studied the basal level expression and activation 
Figure 1 Osimertinib-resistant NSCLC cell lines protein characterization. (A) Western blot analysis shows endogenous protein levels in five 
NSCLC osimertinib-resistant cell lines, namely PC9-OR1, PC9-OR2, PC9-OR3, PC9-OR4 and PC9-OR5, compared to parental cell line 
PC9. α-tubulin was used as protein housekeeping. The experiments were done twice. (B) IC50 values of NSCLC osimertinib-resistant cell 
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of several proteins, such as, membrane receptors, protein 
receptor tyrosine kinase signaling, cancer stem cell 
markers, and proteins involved in apoptosis and cell cycle, 
to investigate whether the PC9-ORs cell lines influence 
protein expression and activation. The most important 
change when comparing the PC9 parental cell line with 
PC9-ORs was: in all five PC9-ORs cells AKT was activated, 
in three, Stat3 was activated, and in four, YAP was activated. 
There was overexpression of EMT marker AXL and IGF1R 
activation in two of them. There is also overexpression of 
antiapoptotic protein bcl-2 in three PC9-ORs (Figure 1). 
We described that the CSC marker Hes1 is overexpressed 
in four PC9-ORs (34). 
Hsp90 inhibitors potentiate the effects of osimertinib in cell 
viability and colony formation inhibition 
It has previously been described that ganetespib exhibits 
cytotoxic activity against NSCLC lines with EGFR 
mutations and also showed activity against erlotinib-resistant 
NSCLC tumor phenotypes in vitro (35,36).
To determine the ganetespib and luminespib antitumoral 
activity in the context of EGFR-mutated cell lines (PC9, H1975) 
and osimertinib-resistant cell lines (PC9-OR2 and PC9-OR4), 
cells were treated for 72 h with the Hsp90 inhibitors, ganetespib 
and luminespib, in a dose-dependent manner to determine if 
they inhibit cell viability in theses cancer cell lines.
As shown in Figure 2A, the cell viability of both resistant 
Figure 2 Combination of Hsp90 inhibitors plus osimertinib potentiate cell viability inhibition. (A) Hsp90 inhibition was assayed in EGFR-
mutated cell lines, PC9 and H1975, and osimertinib-resistant cell lines, PC9-OR2 and PC9-OR4. Cells were exposed to increasing 
concentrations of ganetespib or luminespib for 72 h and cell viability was analyzed by MTT assay. The experiments were performed in 
triplicate. (B) Combination of ganetespib or luminespib with osimertinib in osimertinib-resistant cell lines. Cells were exposed to increasing 
concentration of ganetespib or luminespib combined with increasing concentrations of osimertinib for 72 h and cell viability was analyzed 
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and parental cell lines was similarly affected by each Hsp90 
inhibitor. Ganetespib and luminespib caused a dose-dependent, 
cell viability decrease of 12.5–15 nM in both compounds.
To determine whether Hsp90 inhibitors could overcome 
intrinsic resistance to osimertinib and synergize with 
osimertinib in PC9-OR cells, we exposed PC9-OR2 and 
PC9-OR4 cells to different doses of osimertinib plus 
ganetespib or luminespib. In these studies, the combination 
of luminespib plus osimertinib in both cell lines and 
ganetespib plus osimertinib in PC9-OR4 cell line clearly 
potentiates a decrease of cell viability (Figure 2). 
Furthermore, colony formation assays indicate that 
PC9, H1975, PC9-OR2 and PC9-OR4 cells incubated 
with osimertinib and luminespib, in a dose-dependent 
experiment, were sensitive to the combination, significantly 
reducing the number of colonies better than single 
luminespib treatment, showing a clear effect at 2 nM of 
luminespib plus osimertinib. Thus, combination treatment 
reduces the formation of new colonies greater than single 
luminespib or osimertinib strategy (Figure 3).
Luminespib decreases expression and activation of proteins 
involved in osimertinib-resistance 
To assess the effect of luminespib in expression and 
activation of proteins related to osimertinib-resistance, 
Figure 3 Combination of Hsp90 inhibitor luminespib plus osimertinib potentiate colony formation inhibition. EGFR-mutated cell lines 
PC9 and H1975 and osimertinib-resistant cell lines PC9-OR2 and PC9-OR4 were exposed to increasing doses of luminespib alone (0, 0.5, 
1, 2, 3, 5 nM) or in combination with osimertinib (50 nM) for 12 days. The experiments were done at least twice and a representative colony 
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Western blotting analyses were conducted. In a dose-
response experiment with PC9-OR2 and PC9-OR4 cells 
exposed to increasing luminespib concentrations, it was 
observed that the Hsp90 inhibitor attenuated protein 
expression, in a dose-dependent manner, of membrane 
receptors EGFR, MET and AXL, that are protein clients 
of Hsp90 (16,17) and, in a lesser manner, the downstream 
molecules of signaling pathways related to membrane 
receptors, such as, AKT and Stat3, which are described 
as Hsp90 client proteins (16,17), and YAP (Figure 4). We 
described that the CSC marker Hes1 is overexpressed in 
four PC9-ORs (35). 
Concomitant reduction has also been observed in the 
phosphorylation of the membrane receptors EGFR, MET, 
downstream signaling molecules Stat3, AKT, Erk1/2 YAP 
and Src (Figure 4).
There were no protein level changes of signaling 
molecules Src, Erk1/2, β-catenin at the doses of luminespib 
used (Figure 4).
In apoptotic related proteins, there are no changes in 
PARP cleavage in the PC9-OR2 cell line, but an increase of 
PARP cleaved protein was appreciated in the PC9-OR4 cell 
line. There is a decrease in bcl2 expression that is clearer 
in the PC9-OR4 cell line. There are no significant changes 
in caspase 8 expression (Figure 4). Finally, a slight protein 
expression decrease was observed in cell cycle related 
proteins, p14 in PC9-OR2 and p16 in PC9-OR4 (Figure 4).
Luminespib sensitizes osimertinib-resistant cell lines to 
osimertinib
As we have observed before that luminespib was able 
to decrease expression or activation of several proteins 
involved in osimertinib-resistance, we wanted to study the 
capacity of luminespib to potentiate the effect of osimertinib 
in osimertinib-resistant cell lines. Then, to determine 
whether luminespib can enhance the antitumor effect of 
osimertinib, we treated PC9-OR2 and PC9-OR4 cells with 
increasing doses of luminespib alone, or in combination 
with a constant dose of osimertinib (50 nM), for 24 h, 
and analyzed the effect of the luminespib plus osimertinib 
combination.
We assessed that the osimertinib and luminespib 
combination causes and important effect in protein 
expression of YAP and AKT in PC9-OR4 and bcl2 in PC9-
OR2 and the CSC marker Bmi1 in PC9-OR4. There is a 
clear protein expression downregulation of p14 in PC9-
OR2 and p16 in PC9-OR4 cell cycle markers (Figure 4). 
Also, we have to note that osimertinib increases the 
phosphorylation of Stat3, AKT and Src in both cell lines 
and YAP in PC9-OR2, and luminespib was able to reverse 
this activation (Figure 4).
Taken together, our studies indicate that the dual 
treatment of Hsp90 inhibitors plus osimertinib partially 
overcomes osimertinib-resistance in these tumor cell lines.
Clinical activity of ganetespib in one lung cancer patient 
harboring an exon 20 EGFR mutation
A 29-year-old female, never smoker, was diagnosed with 
advanced NSCLC patient after presenting with cough, 
dyspnea and hemoptysis. Imaging studies revealed 
metastatic involvement of the mediastinal lymph nodes, 
multiple pleural implants and severe pleural effusion. A 
pleural biopsy allowed confirmatory diagnosis of metastatic 
lung adenocarcinoma and EGFR testing was performed 
detecting an exon 20 T790M mutation. No known EGFR 
sensitizing mutation was detected. Other actionable 
alterations were not routinely tested at our institution at 
that time. 
Initial therapy with erlotinib was ineffective and resulted 
in symptomatic tumor progression within the first month 
of treatment. Patient was then enrolled in an afatinib 
phase 2 clinical trial but again, disease progression was the 
best response after 8 weeks of treatment. Three cytotoxic 
chemotherapy lines of treatment were subsequently 
administered (including platinum-gemcitabine, pemetrexed 
and paclitaxel-bevacizumab) with short-lived clinical 
benefit allowing 2 years of survival at the cost several 
chronic sequels due to cumulative toxicity. By April 2012 
the disease had spread with new brain and bone metastases. 
At that point, patient started ganetespib treatment under a 
compassionate use program. The best response assessment 
showed brain and femur metastasis partial response 
(Figure 5) and the duration of the response was 8 months. 
Ganetespib tolerance was adequate with asthenia and mild 
diarrhea as only reported side effects (Figure 5).
Discussion
Osimertinib has been approved by FDA for treating 
patients with EGFR T790M mutant NSCLC with 
disease progression on or after EGFR TKI treatment, 
however,  re s i s t ance  to  th i s  drug  emerged .  The 
mechanisms of resistance could be EGFR dependent or 
EGFR independent, and several strategies to overcome 
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Figure 4 Combination of Hsp90 inhibitor luminespib with osimertinib downregulates expression and inhibits activation of proteins 
involved in osimertinib-resistance. PC9-OR4 (A) and PC9-OR2 (B) cell lines were incubated with the indicated increasing concentrations of 
luminespib alone or in combination with osimertinib (50 nM) for 24 h. Protein expression and activation were analyzed by Western blotting 
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Figure 5 Response of ganetespib in a non-small cell lung cancer patient harboring a 790M mutation in EGFR exon 20. Positron emission 
tomography-computed tomography (PET-CT) scans disclosing fluorine-18-fluorodeoxyglucose (FDG) avid lesions and nuclear magnetic 
resonance (NMR) in a woman with non-small cell lung cancer harboring EGFR 790 mutation, before and after ganetespib therapy. Decrease 
in size lesions is noted in femur metastatic tumoral lesion (A) and brain metastatic tumoral lesion (B).
osimertinib-resistance have been assayed.
Many of the proteins involved in mutant EGFR proteins 
are particularly reliant on the chaperone activity on Hsp90 
for their conformational stability and function (18,37). 
For this reason, the use of Hsp90 inhibitors that leads to 
the degradation of mutant proteins involved in EGFRTKI 
resistance, has been assayed to treat EGFR mutant tumors, 
as well as WT EGFR tumors (38). However, the clinical 
results with Hsp90 inhibitors revealed a modest single-agent 
activity in WT or mutant EGFR NSCLC patients (39,40). 
As a result, Hsp90 inhibitors have been used in combination 
with other drugs. For example, ganetespib has shown potent 
chemosensitizing activity when combined with taxanes in 
NSCLC (20,41). Also, Hsp90 inhibitors have shown good 
efficiency in EGFR-TKI resistant cells (18). It has been 
described that the Hsp90 inhibitor luminespib was active 
in patients with NSCLC, particularly among patients with 
ALK rearrangements and EGFR mutations (33) KRAS-
mutant cell lines with LKB loss showed enhanced sensitivity 
to Hsp90 inhibition (42,43).
Acquired resistance to EGFR TKIs is usually due 
to the development of a T790M mutation in EGFR 
exon 20. Luminespib and ganetespib showed antitumor 
activity against H1975, which harbors T790M and L858R 
mutations (8). 
We have generated five osimertinib-resistant cell 
lines from the EGFR mutant NSCLC cell line, PC9 and 
analyzed the molecular profile of these cell models. Many of 
the proteins overexpressed or activated in these osimertinib-
resistant cell lines are client proteins of Hsp90, and, for 
this reason, we hypothesize that the combination of Hsp90 
inhibitors and osimertinib could be an adequate strategy to 
overcome osimertinib-resistance.
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of osimertinib and the Hsp90 inhibitors, ganetespib and 
luminespib, on inhibiting the growth of lung cancer cells, 
and similar effects have been seen in colony-formation 
assays. Therefore, the combination of Hsp90 inhibitors 
with osimertinib could be a promising therapeutic 
strategy for osimertinib-resistant NSCLC patients. Hsp90 
inhibition was seen to induce sensitivity to osimertinib 
in osimertinib-resistant cell lines. The concurrent 
treatment with luminespib and osimertinib resulted in a 
significantly improved antitumor response, indicating that 
dual treatment may provide a good strategy to overcome 
osimertinib-resistance. This should be evaluated further in 
clinical trials.
We then analyzed, by Western blotting technique, the 
molecular basis underlying the superior efficacy of the 
combinatorial strategy over single agent treatment, since 
Hsp90 inhibition could have a convergent impact, or 
parallel signaling pathways, to the EGFR pathway.
The Hsp90 inhibitor luminespib, decreases the protein 
expression of membrane receptors, such as EGFR, 
MET and AXL, and, in a lesser manner, the downstream 
molecules, YAP, Stat3, AKT, Src, Mcl1, the apoptosis 
marker Bim and cell cycle marker p14. This treatment, also 
decreases the phosphorylation of EGFR and MET, with 
concomitant effects on downstream pathways, including, 
Stat3, AKT, YAP, Src and Erk1/2. 
The addition of luminespib to osimertinib treatment 
attenuated the expression of downstream signaling 
molecules, Stat3 and AKT, and the CSC marker, Bmi1. 
It also affects the activation of EGFR and Erk1/2. One 
remarkable effect is that luminespib decreases the activation 
caused by osimertinib of MET, Stat3, AKT and Src. 
As an example of the potential clinical activity of Hsp90 
inhibitors in EGFR mutant patients we described the 
evolution of a patient case that showed significant benefit 
from ganetespib monotherapy. At that moment, osimertinib 
was not available but based on our results the combined 
treatment would have been an excellent opportunity for our 
patient.
In conclusion, our results focused on the role of Hsp90 
inhibition as a potential therapeutic option in combination 
with osimertinib against osimertinib-resistant NSCLC.
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